

# Supplementary Materials: Characterization and Risk Assessment of PM<sub>2.5</sub>-Bound Polycyclic Aromatic Hydrocarbons and their Derivatives Emitted from a Typical Pesticide Factory in China

Diwei Wang <sup>1,2</sup>, Shengmin Wu <sup>2,\*</sup>, Xuesong Gong <sup>3,\*</sup>, Tao Ding <sup>2</sup>, Yali Lei <sup>4</sup>, Jian Sun <sup>1</sup> and Zhenxing Shen <sup>1</sup>

<sup>1</sup> Department of Environmental Science and Engineering, Xi'an Jiaotong University, Xi'an 710049, China

<sup>2</sup> The State Key Laboratory of Environmental Assessment and Pollution Control of Pesticides for Environmental Protection, Nanjing Institute of Environmental Sciences, Ministry of Ecological Environment, Nanjing 210042, China; dingtao@xpu.edu.cn

<sup>3</sup> School of Environmental and Chemical Engineering, Xi'an Polytechnic University, Xi'an 710048, China

<sup>4</sup> Key Lab of Geographic Information Science of the Ministry of Education, School of Geographic Sciences, East China Normal University, Shanghai 200241, China; yllel@geo.ecnu.edu.cn

\* Correspondence: wsm@nies.org (S.W.); xsgong@xpu.edu.cn (X.G.)

**Contents:**

Text S1. The risk assessment of exposure to PM<sub>2.5</sub>-bound PAHs emission from pesticide factory.

Table S1. The meteorological parameters, including temperature (T), relative humidity (RH), wind speed (WS), and wind direction (WD) during the sampling period.

Table S2. Individual profile of detected PAHs in this study.

Table S3. Toxicity equivalent factor (TEF) and mutagenic potency factor (MEF) values for individual PAHs species.

Table S4. Parameters used in the incremental lifetime cancer risk (ILCR) estimation.

Table S5. The average concentration of individual PAHs species (ng/m<sup>3</sup>).

Table S6. The TEQ and MEQ of individual PAHs species during the sampling period.

Figure S1. The map of the sampling area. The red star indicates the target pesticide factory, and the blue ball indicates the sampling point. The map was obtained on the website <https://www.tianditu.gov.cn/>. Last access date: 15 July 2023.

Text S1. The risk assessment of exposure to PM<sub>2.5</sub>-bound PAHs emission from pesticide factory.

### 1. Total carcinogenic equivalent toxicity (TEQ)

The TEQ was calculated according to PAHs concentrations and toxicity equivalent factor (TEF), and following equation (1):

$$\Sigma\text{TEQ} = \Sigma C_i \times \text{TEF}_i \quad (1)$$

where  $C_i$  is the  $i$ -th PAHs concentration (ng/m<sup>3</sup>);  $\text{TEF}_i$  are the TEF of the  $i$ -th PAHs. TEF values for individual PAHs were obtained from previous literature [1–3]. In this study, a total of 28 TEF of PAHs were used, including 18 p-PAHs, 1 a-PAHs, 1 o-PAHs and 8 n-PAHs, as summarized in Table S3.

### 2. Total mutagenic equivalent toxicity (MEQ)

The MEQ was calculated according to PAHs concentrations and mutagenic potency factor (MEF), and following equation (2):

$$\Sigma\text{MEQ} = \Sigma C_i \times \text{MEF}_i \quad (2)$$

where  $C_i$  is the  $i$ -th PAHs concentration (ng/m<sup>3</sup>);  $\text{MEF}_i$  are the MEF of the  $i$ -th PAHs. As summarized in Table S3, a total of 8 MEF of p-PAHs were found in previous study [4] and were used in present study.

### 3. Incremental lifetime cancer risk (ILCR)

The ILCR caused by inhalation, ingestion and dermal contact was calculated using the United States Environmental Protection Agency (US EPA) standard models [5,6] as following equation (3)–(6):

$$ILCR_{\text{Inhalation}} = \frac{CS \times (CSF_{\text{Inhalation}} \times \sqrt[3]{\left(\frac{BW}{70}\right)}) \times IR_{\text{Inhalation}} \times EF \times ED}{BW \times AT \times PEF} \quad (3)$$

$$ILCR_{\text{Ingestion}} = \frac{CS \times (CSF_{\text{Ingestion}} \times \sqrt[3]{\left(\frac{BW}{70}\right)}) \times IR_{\text{Ingestion}} \times EF \times ED}{BW \times AT \times 10^6} \quad (4)$$

$$ILCR_{\text{Dermal}} = \frac{CS \times (CSF_{\text{Dermal}} \times \sqrt[3]{\left(\frac{BW}{70}\right)}) \times SA \times AF \times ABS \times EF \times ED}{BW \times AT \times 10^6} \quad (5)$$

$$ILCR = ILCR_{\text{Inhalation}} + ILCR_{\text{Ingestion}} + ILCR_{\text{Dermal}} \quad (6)$$

where CS is the sum of converted PM<sub>2.5</sub>-bound PAHs concentrations based on the TEF (mg kg<sup>-1</sup>), CSF is carcinogenic slope factor (mg kg<sup>-1</sup> d<sup>-1</sup>)<sup>-1</sup>, BW is body weight (kg), IR<sub>Inhalation</sub> is the inhalation rate (m<sup>3</sup> d<sup>-1</sup>), IR<sub>Ingestion</sub> is the soil intake rate (mg d<sup>-1</sup>), EF is the exposure frequency (d year<sup>-1</sup>), ED is the exposure duration (year), AT is the average life span (year), PEF is the soil dust produce factor (m<sup>3</sup> kg<sup>-1</sup>), SA is the dermal surface exposure (cm<sup>2</sup> d<sup>-1</sup>), AF is the dermal adherence factor (mg cm<sup>-2</sup>), ABS is the dermal adsorption fraction. All the used parameters in the ILCR model in present study are listed in Table S4.

#### 4. Loss of life expectancy (LLE)

LLE is the loss in expectation of life caused by carcinogenic risk, which is a new environmental health risk assessment technology that normalizes and compares the carcinogenic risk and non-carcinogenic risk caused by environmental pollution [7]. Previous studies have shown that the LLE equivalent of adults corresponding to the 10<sup>-5</sup> of ILCR caused by pollution exposure was 51.2 min [7]. The LLE caused by carcinogenesis of PAHs was calculated as following equation (7):

$$\text{LLE} = 51.2 \times (\text{ILCR}/10^{-5}) \quad (7)$$

Table S1. The meteorological parameters, including temperature (T), relative humidity (RH), wind speed (WS), and wind direction (WD) during the sampling period.

| Date            | T (°C) | RH (%) | WD        | WS (m/s) |
|-----------------|--------|--------|-----------|----------|
| 2023.3.15 day   | 5~14   | 70     | Northeast | 7        |
| 2023.3.15 night | 6~14   | 75     | East      | 5        |
| 2023.3.16 day   | 4~13   | 90     | East      | 5        |
| 2023.3.16 night | 4~13   | 83     | East      | 5        |
| 2023.3.17 day   | 1~9    | 87     | Northeast | 4        |
| 2023.3.17 night | 1~9    | 68     | Northeast | 1        |
| 2023.3.18 day   | -1~15  | 70     | Northwest | 2        |
| 2023.3.18 night | 1~15   | 70     | Southwest | 1        |
| 2023.3.19 day   | 2~17   | 70     | Southeast | 2        |
| 2023.3.19 night | 2~17   | 62     | Southeast | 2        |
| 2023.3.20 day   | 3~18   | 66     | Southeast | 3        |
| 2023.3.20 night | 3~18   | 76     | Southeast | 2        |
| 2023.3.21 day   | 7~18   | 84     | East      | 3        |
| 2023.3.21 night | 7~18   | 84     | Northeast | 3        |
| 2023.3.22 day   | 10~14  | 95     | Northeast | 3        |
| 2023.3.22 night | 10~14  | 94     | North     | 4        |
| 2023.3.23 day   | 8~17   | 45     | Northeast | 6        |
| 2023.3.23 night | 8~17   | 35     | East      | 4        |

Table S2. Individual profile of detected PAHs in this study.

|                     | PAHs species                  | Abbreviation | Molar weight<br>(g/mol) | Rings |
|---------------------|-------------------------------|--------------|-------------------------|-------|
| Parent-<br>PAHs     | acenaphthylene                | ACY          | 152.20                  | 2     |
|                     | acenaphthene                  | ACE          | 154.21                  | 2     |
|                     | fluorene                      | FLO          | 166.22                  | 2     |
|                     | phenanthrene                  | PHE          | 178.23                  | 3     |
|                     | anthracene                    | ANT          | 178.23                  | 3     |
|                     | fluoranthene                  | FLA          | 202.26                  | 4     |
|                     | pyrene                        | PYR          | 202.25                  | 4     |
|                     | benzo[a]anthracene            | BaA          | 228.29                  | 4     |
|                     | chrysene                      | CHR          | 228.29                  | 4     |
|                     | benzo[b]fluoranthene          | BbF          | 252.31                  | 4     |
|                     | benzo[j+k]fluoranthene        | BkF          | 252.31                  | 4     |
|                     | benzo[a]fluoranthene          | BaF          | 252.31                  | 4     |
|                     | benzo[e]pyrene                | BeP          | 252.31                  | 5     |
|                     | benzo[a]pyrene                | BaP          | 252.31                  | 5     |
|                     | perylene                      | PER          | 252.31                  | 5     |
|                     | indeno[1,2,3-cd]pyrene        | IcdP         | 276.33                  | 5     |
|                     | dibenzo[a,h]anthracene        | DBahA        | 278.35                  | 5     |
|                     | benzo[ghi]perylene            | BghiP        | 276.33                  | 6     |
|                     | coronene                      | COR          | 300.35                  | 6     |
|                     | dibenzo[a,e]pyrene            | DBaeP        | 302.37                  | 6     |
|                     | cyclopenta[cd]pyrene          | CPcdP        | 226.27                  | 4     |
|                     | picene                        | PIC          | 278.35                  | 5     |
| Alkylated-<br>PAHs  | 2-methylnaphthalene           | 2M-NAP       | 142.20                  | 2     |
|                     | 1-methylnaphthalene           | 1M-NAP       | 142.20                  | 2     |
|                     | 2,6-dimethylnaphthalene       | 2,6DM-NAP    | 156.22                  | 2     |
|                     | 9-methylanthracene            | 9M-ANT       | 192.26                  | 3     |
|                     | methylfluoranthene            | M-FLA        | 216.28                  | 3     |
|                     | retene                        | RET          | 234.34                  | 3     |
|                     | methylchrysene                | M-CHR        | 242.31                  | 4     |
| Oxygenated-<br>PAHs | 1,4-naphthoquinone            | 1,4-NAQ      | 158.15                  | 2     |
|                     | 1-naphthaldehyde              | 1-NAA        | 156.18                  | 2     |
|                     | 1-acenaphthenone              | 1-ACO        | 168.19                  | 2     |
|                     | 9-fluorenone                  | 9-FO         | 180.20                  | 2     |
|                     | 9,10-anthraquinone            | 9,10-ATQ     | 208.21                  | 3     |
|                     | 1,8-naphthalic anhydride      | 1,8-NAA      | 198.17                  | 3     |
|                     | benzo(a)anthracene-7,12-dione | BaAQ         | 258.27                  | 4     |
|                     | 1,4-chrysenequinone           | 1,4-CHRQ     | 258.27                  | 4     |
|                     | 5,12-naphthacenequinone       | 5,12-NAAQ    | 258.27                  | 4     |
|                     | 6H-benzo(c,d)pyrene-6-one     | 6H-BcdPO     | 254.28                  | 5     |
|                     | benzanthrone                  | BZA          | 230.26                  | 4     |
| Nitrated-<br>PAHs   | 2-nitrobiphenyl               | 2N-BIP       | 199.20                  | 2     |
|                     | 5-nitroacenaphthene           | 5N-ACE       | 199.21                  | 2     |
|                     | 2-nitrofluorene               | 2N-FLO       | 211.22                  | 2     |
|                     | 9-nitrophenanthrene           | 9N-PHE       | 223.23                  | 3     |
|                     | 9-nitroanthracene             | 9N-ANT       | 223.23                  | 3     |

|                       |           |        |   |
|-----------------------|-----------|--------|---|
| 3-nitrofluoranthene   | 3N-FLA    | 247.25 | 4 |
| 1-nitropyrene         | 1N-PYR    | 247.26 | 4 |
| 2,7-dinitrofluorene   | 2,7DN-FLO | 256.21 | 2 |
| 6-nitrochrysene       | 6N-CHR    | 273.29 | 4 |
| 1,3-dinitropyrene     | 1,3-DNP   | 292.26 | 4 |
| 1,6-dinitropyrene     | 1,6-DNP   | 292.26 | 4 |
| 6-nitrobenzo(a)pyrene | 6N-BaP    | 297.31 | 5 |

---

Table S3. Toxicity equivalent factor (TEF) and mutagenic potency factor (MEF) values for individual PAHs species.

| PAHs species               | Abbreviation | TEF                   | MEF                  |
|----------------------------|--------------|-----------------------|----------------------|
| Acenaphthylene             | ACY          | 0.001 <sup>[2]</sup>  | -                    |
| Acenaphthene               | ACE          | 0.001 <sup>[2]</sup>  | -                    |
| Fluorene                   | FLO          | 0.001 <sup>[2]</sup>  | -                    |
| Phenanthrene               | PHE          | 0.001 <sup>[2]</sup>  | -                    |
| Anthracene                 | ANT          | 0.01 <sup>[2]</sup>   | -                    |
| Fluoranthene               | FLA          | 0.001 <sup>[2]</sup>  | -                    |
| Pyrene                     | PYR          | 0.001 <sup>[2]</sup>  | -                    |
| Benzo[a]Anthracene         | BaA          | 0.1 <sup>[2]</sup>    | 0.082 <sup>[4]</sup> |
| Chrysene                   | CHR          | 0.01 <sup>[2]</sup>   | 0.017 <sup>[4]</sup> |
| Benzo[b]Fluoranthene       | BbF          | 0.1 <sup>[2]</sup>    | 0.25 <sup>[4]</sup>  |
| Benzo[k]Fluoranthene       | BkF          | 0.1 <sup>[2]</sup>    | 0.11 <sup>[4]</sup>  |
| Benzo[e]Pyrene             | BeP          | 0.002 <sup>[1]</sup>  | -                    |
| Benzo[a]Pyrene             | BaP          | 1 <sup>[2]</sup>      | 1 <sup>[4]</sup>     |
| Indeno[1,2,3-cd]Pyrene     | IcdP         | 0.1 <sup>[2]</sup>    | 0.31 <sup>[4]</sup>  |
| Dibenzo[a, h]Anthracene    | DBahA        | 5 <sup>[2]</sup>      | 0.29 <sup>[4]</sup>  |
| Benzo[g, h, i]Perylene     | BghiP        | 0.01 <sup>[2]</sup>   | 0.19 <sup>[4]</sup>  |
| Dibenzo[a, e]Pyrene        | DBaeP        | 2.9 <sup>[1]</sup>    | -                    |
| 2-Methylnaphthalene        | 2M-NAP       | 0.001 <sup>[2]</sup>  | -                    |
| Cyclopenta[cd]Pyrene       | CPcdP        | 6.9 <sup>[1]</sup>    | -                    |
| 6H-Benzo(c, d)Pyrene-6-One | BcdPO        | 0.32 <sup>[1]</sup>   | -                    |
| 5-Nitroacenaphthene        | 5N-ACE       | 0.01 <sup>[3]</sup>   | -                    |
| 2-Nitrofluorene            | 2N-FLO       | 0.01 <sup>[3]</sup>   | -                    |
| 9-Nitroanthracene          | 9N-ANT       | 0.0032 <sup>[1]</sup> | -                    |
| 3-Nitrofluoranthene        | 3N-FLA       | 0.0026 <sup>[1]</sup> | -                    |
| 1-Nitropyrene              | 1N-PYR       | 0.1 <sup>[1]</sup>    | -                    |
| 6-Nitrochrysene            | 6N-CHR       | 10 <sup>[3]</sup>     | -                    |
| 1,3-Dinitropyrene          | 1,3-DNP      | 0.031 <sup>[1]</sup>  | -                    |
| 1,6-Dinitropyrene          | 1,6-DNP      | 0.28 <sup>[1]</sup>   | -                    |

“-” represents not available.



Table S4. Parameters used in the incremental lifetime cancer risk (ILCR) estimation.

| Parameters  | Male adult           | Female adult         | References |
|---|----------------------|----------------------|------------|
| Body weight (BW) (kg)   | 71.4                 | 63                   | [8]        |
| CSF <sub>Inhalation</sub> (mg·kg <sup>-1</sup> ·d <sup>-1</sup> ) <sup>-1</sup> | 3.85                 | 3.85                 | [6]        |
| CSF <sub>Ingestion</sub> (mg·kg <sup>-1</sup> ·d <sup>-1</sup> ) <sup>-1</sup>  | 7.3                  | 7.3                  | [6]        |
| CSF <sub>Dermal</sub> (mg·kg <sup>-1</sup> ·d <sup>-1</sup> ) <sup>-1</sup>     | 25                   | 25                   | [6]        |
| Inhalation rate (IR <sub>Inhalation</sub> ) (m <sup>3</sup> ·d <sup>-1</sup> )  | 18.7                 | 15.1                 | [8]        |
| Soil intake rate (IR <sub>Ingestion</sub> ) (m <sup>3</sup> ·d <sup>-1</sup> )  | 100                  | 100                  | [9]        |
| Exposure frequency (EF) (d·a <sup>-1</sup> )                                    | 180                  | 180                  | [10]       |
| Exposure duration (ED)(a)   | 30                   | 30                   | [8]        |
| Averaging life span (AT) (d)  | 25550                | 25550                | [11]       |
| Dermal exposure area (SA) (cm <sup>2</sup> )                                    | 5700                 | 5700                 | [9]        |
| Dermal adherence factor (AF) (mg·cm <sup>-2</sup> )                             | 0.07                 | 0.07                 | [9]        |
| Dermal adsorption fraction (ABS)  | 0.13                 | 0.13                 | [9]        |
| Particle emission factor (PEF) (m <sup>3</sup> ·kg <sup>-1</sup> )              | 1.36·10 <sup>9</sup> | 1.36·10 <sup>9</sup> | [9]        |

Table S5. The average concentration of individual PAHs species (ng/m<sup>3</sup>).

| PAHs species |           | Daily<br>(n = 17) | Daytime<br>(n = 9) | Nighttime<br>(n = 8) |
|--------------|-----------|-------------------|--------------------|----------------------|
| p-PAHs       | ACY       | 4.32±3.27         | 4.11±3.81          | 4.56±2.78            |
|              | ACE       | 1.71±1.04         | 1.81±1.28          | 1.61±0.76            |
|              | FLO       | 3.31±2.32         | 3.56±3.00          | 3.03±1.36            |
|              | PHE       | 2.69±2.34         | 2.74±2.85          | 2.64±1.79            |
|              | ANT       | 1.29±0.67         | 1.36±0.84          | 1.21±0.45            |
|              | FLA       | 6.80±5.68         | 7.07±6.98          | 6.51±4.21            |
|              | PYR       | 9.04±7.52         | 9.66±9.30          | 8.34±5.40            |
|              | BaA       | 4.24±4.11         | 4.05±4.15          | 4.44±4.34            |
|              | CHR       | 8.21±5.46         | 8.63±7.03          | 7.75±3.37            |
|              | BbF       | 6.31±4.46         | 6.15±5.21          | 6.49±3.80            |
|              | BkF       | 6.27±6.41         | 6.28±7.6           | 6.26±5.29            |
|              | BaF       | 3.16±2.60         | 3.22±3.14          | 3.10±2.03            |
|              | BeP       | 8.47±7.87         | 9.05±9.95          | 7.82±5.25            |
|              | BaP       | 7.58±5.41         | 7.76±6.44          | 7.36±4.41            |
|              | PER       | 3.77±4.96         | 3.52±5.32          | 4.04±4.87            |
|              | IcdP      | 3.57±2.44         | 3.63±2.75          | 3.51±2.23            |
|              | DBahA     | 4.71±3.41         | 4.78±3.68          | 4.64±3.32            |
|              | BghiP     | 9.66±9.15         | 8.75±8.40          | 10.68±10.43          |
|              | COR       | 5.95±5.45         | 5.85±6.43          | 6.06±4.53            |
|              | DBaP      | 3.52±2.74         | 3.56±3.25          | 3.49±2.26            |
|              | CPcdP     | 2.08±1.76         | 2.06±2.03          | 2.10±1.53            |
|              | PIC       | 5.89±3.77         | 5.80±4.40          | 5.98±3.21            |
| Σp-PAHs      |           | 112.55±89.69      | 113.39±105.97      | 111.61±74.52         |
| a-PAHs       | 2M-NAP    | 2.61±1.88         | 2.79±2.28          | 2.4±1.44             |
|              | 1M-NAP    | 1.24±1.04         | 1.32±1.34          | 1.15±0.66            |
|              | 2,6DM-NAP | 4.13±3.11         | 4.71±3.97          | 3.48±1.80            |
|              | 9M-ANT    | 3.31±3.00         | 3.71±3.92          | 2.86±1.60            |
|              | M-FLA     | 1.75±1.97         | 1.75±2.35          | 1.76±1.60            |
|              | RET       | 3.04±1.86         | 3.12±2.28          | 2.95±1.40            |
|              | M-CHR     | 1.96±1.55         | 1.96±2.00          | 1.95±0.95            |
| Σa-PAHs      |           | 18.05±13.76       | 19.37±17.57        | 16.56±8.66           |
| o-PAHs       | 1,4-NAQ   | 1.84±1.07         | 1.98±1.28          | 1.70±0.85            |
|              | 1-NAA     | 1.58±1.12         | 1.65±1.39          | 1.49±0.79            |
|              | 1-ACO     | 1.08±0.92         | 1.13±1.11          | 1.02±0.71            |
|              | 9-FO      | 11.79±8.94        | 11.81±11.3         | 11.77±6.05           |
|              | 9,10-ATQ  | 10.68±8.93        | 10.96±11.02        | 10.36±6.59           |
|              | 1,8-NAA   | 4.02±3.67         | 4.12±4.62          | 3.92±2.51            |
|              | BaAQ      | 9.37±9.17         | 9.29±11.27         | 9.47±6.87            |
|              | 1,4-CHRQ  | 5.88±4.01         | 6.33±5.28          | 5.37±2.07            |
|              | 5,12-NAAQ | 5.45±4.44         | 5.66±5.60          | 5.20±3.03            |
|              | 6H-BcdPO  | 7.35±7.43         | 7.29±8.67          | 7.42±6.34            |
|              | BZA       | 7.08±6.28         | 6.98±7.93          | 7.20±4.26            |
| Σo-PAHs      |           | 66.13±54.79       | 67.20±68.85        | 64.92±37.94          |
| n-PAHs       | 2N-BIP    | 0.45±0.24         | 0.45±0.29          | 0.45±0.18            |
|              | 5N-ACE    | 0.27±0.13         | 0.28±0.17          | 0.26±0.09            |
|              | 2N-FLO    | 0.20±0.13         | 0.22±0.17          | 0.18±0.08            |
|              | 9N-PHE    | 0.15±0.08         | 0.15±0.10          | 0.15±0.07            |

|           |           |           |           |
|-----------|-----------|-----------|-----------|
| 9N-ANT    | 0.96±0.74 | 1.00±0.96 | 0.92±0.45 |
| 3N-FLA    | 0.30±0.15 | 0.31±0.18 | 0.30±0.12 |
| 1N-PYR    | 0.29±0.18 | 0.29±0.19 | 0.30±0.17 |
| 2,7DN-FLO | 0.26±0.16 | 0.27±0.19 | 0.25±0.13 |
| 6N-CHR    | 0.15±0.09 | 0.15±0.11 | 0.14±0.06 |
| 1,3-DNP   | 0.26±0.14 | 0.26±0.16 | 0.25±0.13 |
| 1,6-DNP   | 0.29±0.17 | 0.29±0.18 | 0.29±0.16 |
| 6N-BaP    | 0.33±0.18 | 0.33±0.21 | 0.32±0.15 |
| Σn-PAHs   | 3.90±2.24 | 4.00±2.79 | 3.80±1.61 |

Table S6. The TEQ and MEQ of individual PAHs species during the sampling period.

| PAHs species | TEQ (ng/m <sup>3</sup> ) | MEQ (ng/m <sup>3</sup> ) |
|--------------|--------------------------|--------------------------|
| ACY          | 0.004±0.003              | -                        |
| ACE          | 0.002±0.001              | -                        |
| FLO          | 0.003±0.002              | -                        |
| PHE          | 0.003±0.002              | -                        |
| ANT          | 0.013±0.007              | -                        |
| FLA          | 0.007±0.006              | -                        |
| PYR          | 0.009±0.008              | -                        |
| BaA          | 0.424±0.411              | 0.347±0.337              |
| CHR          | 0.082±0.055              | 0.14±0.093               |
| BbF          | 0.631±0.446              | 1.578±1.116              |
| BkF          | 0.627±0.641              | 0.689±0.705              |
| BeP          | 0.017±0.016              | -                        |
| BaP          | 7.575±5.41               | 7.575±5.41               |
| IcdP         | 0.357±0.244              | 1.107±0.756              |
| DBahA        | 23.556±17.039            | 1.366±0.988              |
| BghiP        | 0.097±0.092              | 1.836±1.739              |
| DBaeP        | 10.222±7.955             | -                        |
| CPcdP        | 14.327±12.131            | -                        |
| 2M-NAP       | 0.003±0.002              | -                        |
| BcdPO        | 2.352±2.376              | -                        |
| 5N-ACE       | 0.003±0.001              | -                        |
| 2N-FLO       | 0.002±0.001              | -                        |
| 9N-ANT       | 0.003±0.002              | -                        |
| 3N-FLA       | 0.001±0.0004             | -                        |
| 1N-PYR       | 0.029±0.018              | -                        |
| 6N-CHR       | 1.489±0.908              | -                        |
| 1,3-DNP      | 0.008±0.004              | -                        |
| 1,6-DNP      | 0.08±0.047               | -                        |

“-“ represents not available.



Fig. S1 The map of the sampling area. The red star indicates the target pesticide factory, and the blue ball indicates the sampling point. The map was obtained on the website <https://www.tianditu.gov.cn/>. Last access date: 15 July 2023.

## Reference:

1. Durant, J.L.; Busby, W.F., Jr.; Lafleur, A.L.; Penman, B.W.; Crespi, C.L. Human cell mutagenicity of oxygenated, nitrated and unsubstituted polycyclic aromatic hydrocarbons associated with urban aerosols. *Mutat. Res. Genet. Toxicol.* **1996**, *371*, 123–157.
2. Nisbet, I.C.; Lagoy, P.K. Toxic equivalency factors (TEFs) for polycyclic aromatic hydrocarbons (PAHs). *Regul. Toxicol. Pharmacol.* **1992**, *16*, 290–300.
3. Wei, C.; Han, Y.; Bandowe, B.A.; Cao, J.; Huang, R.J.; Ni, H.; Tian, J.; Wilcke, W. Occurrence, gas/particle partitioning and carcinogenic risk of polycyclic aromatic hydrocarbons and their oxygen and nitrogen containing derivatives in Xi'an, central China. *Sci. Total Environ.* **2015**, *505*, 814–822.
4. Jung, K.H.; Yan, B.; Chillrud, S.N.; Perera, F.P.; Whyatt, R.; Camann, D.; Kinney, P.L.; Miller, R.L. Assessment of benzo(a)pyrene-equivalent carcinogenicity and mutagenicity of residential indoor versus outdoor polycyclic aromatic hydrocarbons exposing young children in New York City. *Int. J. Environ. Res. Public Health* **2010**, *7*, 1889–1900.
5. Chen, S.C.; Liao, C.M. Health risk assessment on human exposed to environmental polycyclic aromatic hydrocarbons pollution sources. *Sci. Total Environ.* **2006**, *366*, 112–123.
6. Peng, C.; Chen, W.; Liao, X.; Wang, M.; Ouyang, Z.; Jiao, W.; Bai, Y. Polycyclic aromatic hydrocarbons in urban soils of Beijing: Status, sources, distribution and potential risk. *Environ. Pollut.* **2011**, *159*, 802–808.
7. Guo, X.; Chen, F.; Lu, J.; Zhang, W. Seasonal variation, sources, and risk assessment of PM<sub>2.5</sub>-bound PAHs in Nantong, China: A pre- and post-COVID-19 case study. *Front. Environ. Sci.* **2022**, *10*, 947705.
8. An, Y.Q.; Hao, H.Y.; Jin, H.; Yuan, S.H.; Pei, X.K.; Yang, N.J.; Liu, Y.G. Pollution level and health risk assessment of polycyclic aromatic hydrocarbons in PM<sub>2.5</sub> of four cities in Hebei Province. *Occup and Health.* **2018**, *34*, 3129-3133. (In Chinese)
9. Wang, W.; Huang, M.J.; Kang, Y.; Wang, H.S.; Leung, A.O.; Cheung, K.C.; Wong, M.H. Polycyclic aromatic hydrocarbons (PAHs) in urban surface dust of Guangzhou, China: Status, sources and human health risk assessment. *Sci. Total Environ.* **2011**, *409*, 4519-4527.
10. Ferreira-Baptista, L.; De Miguel, E. Geochemistry and risk assessment of street dust in Luanda, Angola: A tropical urban environment. *Atmos. Environ.* **2005**, *39*, 4501-4512.
11. Sun, J.; Shen, Z.; Zhang, T.; Kong, S.; Zhang, H.; Zhang, Q.; Niu, X.; Huang, S.; Xu, H.; Ho, K.F.; et al. A comprehensive evaluation of PM<sub>2.5</sub>-bound PAHs and their derivative in winter from six megacities in China: Insight the source-dependent health risk and secondary reactions. *Environ. Int.* **2022**, *165*, 107344.